PMC9404301_01
Next-generation sequencing of tissue before and after Telisotuzumab Vedotin. (A) The RNA-based NGS by QIAact Lung All-in-One assay revealed a KIF5B-MET (K24;M15) fusion. (B) The DNA-based NGS by FoundationOne  CDx after Telisotuzumab Vedotin still revealed KIF5B-MET fusion. The data was provided by the Department of Research and Development, Foundation Medicine Inc. (C) The diagram of KIF5B-MET fusion. NGS, next-generation sequencing.
fonc-12-919123-g001.jpg
PMC9404301_01_fonc-12-919123-g001.jpg
f1
Next-generation sequencing (NGS) by the QIAact Lung All-in-One assay revealed KIF5B-MET fusion ( Figure 1A ), PDGFRA mutation, and RICTOR amplification ( Table 1 ).
Summary of treatment courses mentioned in this case report. The yellow arrowhead indicate the target lesion at disease progression after consolidation therapy with durvalumab, whereas the red arrowhead indicates the target lesion at disease progression after the use of Telisotuzumab Vedotin. ALK, anaplastic lymphoma kinase; CCRT, concurrent chemoradiotherapy; CT, computed tomography; EGFR, epidermal growth factor receptor; IHC, immunohistochemical; NGS, next-generation sequencing; PCR, polymerase chain reaction; ROS1, ROS proto-Oncogene 1.
fonc-12-919123-g002.jpg
PMC9404301_01_fonc-12-919123-g002.jpg
f2
Tumors version 1.1. The patient has been on capmatinib for more than nine months, and no significant adverse events have developed. The treatment course is summarized in  Figure 2 .